NOCIL Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Published 3 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹2.7K Cr

NOCIL aspires to achieve double-digit volume growth, though specific timing within the calendar year is uncertain (Page 9). NOCIL aims for a medium-to-long-term volume CAGR of around 10%, targeting a 10% global market share in rubber chemicals (Page 15). - They remain confident of volume growth despite short-term challenges and see the Dahej expansion ramping up production with strong demand visibility (Pages 4, 6, 8). - EBITDA margins and operating leverage are expected to improve as volumes increase and power cost savings from stabilized turbine operations materialize (Pages 7, 13-14). - Management plans to enhance competitiveness through cost savings, optimized product mix, and volume consolidation (Page 14). - Commercialization of new niche products is underway, expected to contribute in the medium term (Page 15). - Market volatility is acknowledged; however, they emphasize operational excellence, innovation, and long-term customer engagement to sustain profitable growth (Page 15-16). - Short-term margins have contracted (from 14% in FY '24 to approx.

From NOCIL Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹167

Market Cap

₹2.7K Cr

P/E Ratio

38.8

How does NOCIL Ltd rank in Chemicals & Petrochemicals?

Compare NOCIL Ltd against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

NOCIL Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹330 Cr, net profit ₹17 Cr.

Full financials →

📊 Revenue & Sales Performance

→NOCIL aspires to achieve double-digit volume growth, though specific timing within the calendar year is uncertain (Page 9).
→Export volumes showed moderate growth (~3-3.5%) recently, with positive momentum expected from incremental approvals and new product commercializations (Pages 4, 11).
→The Dahej facility expansion targets strong demand visibility, with capacity ramp-up expected in H2 FY 26-27 after trials and approvals (Page 6, 10).
→Domestic market volumes are challenged by dumping pressure; antidumping petitions are in process with outcomes expected in coming months (Pages 3, 15).
→Long-term objective includes expanding global market share toward 10% in the rubber chemical space, aiming for a 10% CAGR medium to long term (Page 15).
→Strategy includes a judicious mix of price and volume tactics to remain competitive and achieve growth (Pages 13, 15).
→Growth is expected to come from a combination of geographical expansion, new product commercialization, and operational excellence (Page 7).

📈 Profitability & Margins

→NOCIL aims for a medium-to-long-term volume CAGR of around 10%, targeting a 10% global market share in rubber chemicals (Page 15).
→They remain confident of volume growth despite short-term challenges and see the Dahej expansion ramping up production with strong demand visibility (Pages 4, 6, 8).
→EBITDA margins and operating leverage are expected to improve as volumes increase and power cost savings from stabilized turbine operations materialize (Pages 7, 13-14).
→Management plans to enhance competitiveness through cost savings, optimized product mix, and volume consolidation (Page 14).
→Commercialization of new niche products is underway, expected to contribute in the medium term (Page 15).
→Market volatility is acknowledged; however, they emphasize operational excellence, innovation, and long-term customer engagement to sustain profitable growth (Page 15-16).
→Short-term margins have contracted (from 14% in FY '24 to approx. 10% in FY '25), but are expected to stabilize with operational improvements and volume ramp-up (Pages 14-15).

See what NOCIL Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→NOCIL has a capex budget of Rs. 250 crores for capacity expansion.
→As of March 2025, about 30% of this capex has been spent, primarily categorized as capital work in progress (CWIP).
→The large part of the expenditure is expected during FY 2025-26.
→Trial production for the additional facility is expected to start in H1 of FY 2026-27.
→Post trials and customer approvals, revenues from the new facility are expected to begin in H2 FY 2026-27.
→Current plant capacity utilization is around 65%-67%, with room to grow to 80%-90% before the new facility is commissioned.
→The expected asset turnover ratio for the rubber chemicals business capex is generally between 1.8 to 2.2.
→The expansion aims to support volume growth and capacity debottlenecking, particularly for key products like Dahej expansion.

💰 Fundraising & Capital Structure

→As of the information provided in the transcript, there is no specific mention of any current or future fundraising through debt or equity by NOCIL Limited.
→The company is focusing on an ongoing capex of about Rs. 250 crores for capacity expansion.
→About 30% of this capex had been spent by March 2025, categorized under capital work in progress (CWIP).
→No details were shared about raising funds through debt or equity to finance this capex.
→Management discussed operational improvements and strategic growth but did not indicate plans for new fundraising initiatives.

See what NOCIL Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

The transcript does not explicitly mention current or expected orderbook/pending orders for NOCIL Limited. However, from the discussion, some insights related to orders and demand visibility are: - Strong demand visibility for the Dahej expansion project, indicating positive order intake for expanded capacity. - Customer engagements are ongoing with traction visible across Asia, Europe, and Americas. - Several new products are in advanced stages of customer trials, expected to commercialize towards the end of the year, which should contribute to future orders. - Volume growth is expected as these new products and capacity expansions ramp up. - Long-term strategic and customer engagements suggest ongoing order pipelines in both domestic and export markets. - The company expects to start seeing volume growth in upcoming quarters from various levels of customer approvals and increased capacity utilization. No specific numbers or exact pending order value details are disclosed in the transcript.

Key Metrics

What NOCIL's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Archean Chemical Industries Ltd (Q1 FY26)
Q1 FY26 standalone EBITDA grew 13% YoY to INR 958 million with 33% margin; consolidated net profit stood at INR 401 million. Key concall takeaways from Archean…
PCBL Chemical Ltd (Q1 FY26)
Plant closures in Europe/North America may open export opportunities, boosting international sales beyond the current 41% mix. Key concall takeaways from PCBL…
Rain Industries Ltd (Q1 FY26)
Carbon segment capacity utilization is around 68%, with efforts to increase utilization underway. Key concall takeaways from Rain Industries's Q1 FY26 earnings…
Styrenix Perfor. (Q1 FY26)
Thailand plant utilization is at 50-55% with potential to increase revenue by 70-80% by ramping up capacity and improving product mix. Key concall takeaways…

Compare:vs Pidilite Inds.vs SRF vs Linde India Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were NOCIL Ltd Q1 FY26 results?

What is NOCIL Ltd share price analysis?

NOCIL Ltd currently shows a neutral. The stock trades at a P/E of 38.8 with a market cap of ₹2,696 Cr. Investors should review the full earnings analysis for detailed insights.

Is NOCIL Ltd planning capital expenditure?

NOCIL has a capex budget of Rs.

Keep NOCIL Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.